AbbVie receives EU approval for Rinvoq as a treatment for non-segmental vitiligo
AbbVie (ABBV) announced that its drug Rinvoq has received European Commission approval for the treatment of adult and adolescent patients aged 12 years or older with non-segmental vitiligo who are candidates for systemic therapy. This marks a significant milestone as Rinvoq becomes the first approved systemic treatment option in this indication within the EU. The approval expands AbbVie's portfolio into dermatology, reinforcing its position in autoimmune and inflammatory diseases. The decision reflects regulatory confidence in Rinvoq’s safety and efficacy profile based on clinical trials that demonstrated meaningful improvements for patients with non-segmental vitiligo.
Tickers: $ABBV
Topics: approval non-segmental vitiligo pharmaceuticals Rinvoq